Dietmar Berger is currently the Chief Medical Officer and Head of Global Development at Sanofi, where he oversees the clinical portfolio of Sanofi across all therapeutic areas. With over 20 years of experience in leadership positions across both large pharmaceutical companies as well as innovative biotech companies, Dr. Berger brings extensive expertise in clinical development and advancing programs all the way to market approval to Abcuro. As a trained hematologist and oncologist, Dr. Berger has extensive experience in therapeutic areas of high relevance to Abcuro’s programs. Prior to Sanofi, he was Global Head of R&D at Atara Biotherapeutics, an off-the-shelf cell therapy company. Previously he held senior positions in clinical development at Amgen, Bayer and Genentech where he served as the Senior Vice President of Global Clinical Development, Hematology/Oncology. Dr. Berger holds an M.D. and Ph.D. from the Albert-Ludwigs University School of Medicine in Freiburg, Germany, where he still maintains an adjunct faculty position.
Berger, Dietmar
Dietmar Berger, MD, PhD
Observer, Chief Medical Officer
and Head of Global Development at Sanofi
Dietmar Berger, MD, PhD
Observer, Chief Medical Officer
and Head of Global Development at Sanofi
Dietmar Berger is currently the Chief Medical Officer and Head of Global Development at Sanofi, where he oversees the clinical portfolio of Sanofi across all therapeutic areas. With over 20 years of experience in leadership positions across both large pharmaceutical companies as well as innovative biotech companies, Dr. Berger brings extensive expertise in clinical development and advancing programs all the way to market approval to Abcuro. As a trained hematologist and oncologist, Dr. Berger has extensive experience in therapeutic areas of high relevance to Abcuro’s programs. Prior to Sanofi, he was Global Head of R&D at Atara Biotherapeutics, an off-the-shelf cell therapy company. Previously he held senior positions in clinical development at Amgen, Bayer and Genentech where he served as the Senior Vice President of Global Clinical Development, Hematology/Oncology. Dr. Berger holds an M.D. and Ph.D. from the Albert-Ludwigs University School of Medicine in Freiburg, Germany, where he still maintains an adjunct faculty position.
